Investigation of the neurochemical, molecular and behavioural properties of the putative lithium-mimetic, ebselen

<p>Lithium is the first choice drug for the treatment of bipolar disorder and it is also used as supplementary therapy for treatment-resistant depression. A leading candidate target of lithium is inositol monophosphatase (IMPase) which is critically involved in signalling via the phosphoinosit...

Full description

Bibliographic Details
Main Author: Antoniadou, I
Other Authors: Sharp, T
Format: Thesis
Published: 2015
_version_ 1826315801863389184
author Antoniadou, I
author2 Sharp, T
author_facet Sharp, T
Antoniadou, I
author_sort Antoniadou, I
collection OXFORD
description <p>Lithium is the first choice drug for the treatment of bipolar disorder and it is also used as supplementary therapy for treatment-resistant depression. A leading candidate target of lithium is inositol monophosphatase (IMPase) which is critically involved in signalling via the phosphoinositide cycle (PI). Ebselen, first developed as an anti-inflammatory and anti-oxidant drug, has recently been shown to inhibit IMPase and therefore is a putative lithium-mimetic.</p> <p>This project aimed to investigate the neuropharmacological effects of ebselen in mouse models relevant to depression. Initial studies examined the function of 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors, which signal through PI cycle. Ebselen attenuated the responses of systemically administered 5-HT<sub>2A</sub> agonists at the behavioural and molecular level; specifically the induction of head twitches and ear scratches and increased immediate early gene (IEG) expression. Lithium produced similar effects to ebselen in the same experiments. In addition, an IMPase inhibitor but not a GSK-3 inhibitor mimicked the effect of ebselen at the behavioural model of 5-HT<sub>2A</sub> receptor function. Ebselen also reduced 5-HT<sub>2C</sub> receptor function, as assessed using IEG expression, and lithium had a similar effect. Ebselen was also found to increase 5-HT synthesis in mouse brain regions as previously reported for lithium. In microdialysis studies, ebselen tended to enhance the increase in extracellular 5-HT levels induced by the SSRI citalopram in hippocampus. This finding was consistent with the observation that ebselen and citalopram increased IEG-expression when administered together but not when administered separately. Lastly, ebselen when administered repeatedly increased the abundance of a variety of gene markers of neuronal plasticity in mouse brain regions. Lithium also increased the abundance of markers of neuronal plasticity.</p> <p>Overall, the present study found that ebselen attenuated 5-HT<sub>2</sub> receptor function and partially augmented the effects of citalopram, while it increased markers of neuronal plasticity. These effects of ebselen were largely mimicked by lithium. These findings show that ebselen has similar neuropharmacological effects to lithium across a range of mouse models relevant to depression. The antidepressant potential of ebselen is discussed.</p>
first_indexed 2024-03-06T19:23:11Z
format Thesis
id oxford-uuid:1acec71c-4203-4337-a67a-401460bfd929
institution University of Oxford
last_indexed 2024-12-09T03:32:52Z
publishDate 2015
record_format dspace
spelling oxford-uuid:1acec71c-4203-4337-a67a-401460bfd9292024-12-01T16:00:13ZInvestigation of the neurochemical, molecular and behavioural properties of the putative lithium-mimetic, ebselenThesishttp://purl.org/coar/resource_type/c_db06uuid:1acec71c-4203-4337-a67a-401460bfd929ORA Deposit2015Antoniadou, ISharp, T<p>Lithium is the first choice drug for the treatment of bipolar disorder and it is also used as supplementary therapy for treatment-resistant depression. A leading candidate target of lithium is inositol monophosphatase (IMPase) which is critically involved in signalling via the phosphoinositide cycle (PI). Ebselen, first developed as an anti-inflammatory and anti-oxidant drug, has recently been shown to inhibit IMPase and therefore is a putative lithium-mimetic.</p> <p>This project aimed to investigate the neuropharmacological effects of ebselen in mouse models relevant to depression. Initial studies examined the function of 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors, which signal through PI cycle. Ebselen attenuated the responses of systemically administered 5-HT<sub>2A</sub> agonists at the behavioural and molecular level; specifically the induction of head twitches and ear scratches and increased immediate early gene (IEG) expression. Lithium produced similar effects to ebselen in the same experiments. In addition, an IMPase inhibitor but not a GSK-3 inhibitor mimicked the effect of ebselen at the behavioural model of 5-HT<sub>2A</sub> receptor function. Ebselen also reduced 5-HT<sub>2C</sub> receptor function, as assessed using IEG expression, and lithium had a similar effect. Ebselen was also found to increase 5-HT synthesis in mouse brain regions as previously reported for lithium. In microdialysis studies, ebselen tended to enhance the increase in extracellular 5-HT levels induced by the SSRI citalopram in hippocampus. This finding was consistent with the observation that ebselen and citalopram increased IEG-expression when administered together but not when administered separately. Lastly, ebselen when administered repeatedly increased the abundance of a variety of gene markers of neuronal plasticity in mouse brain regions. Lithium also increased the abundance of markers of neuronal plasticity.</p> <p>Overall, the present study found that ebselen attenuated 5-HT<sub>2</sub> receptor function and partially augmented the effects of citalopram, while it increased markers of neuronal plasticity. These effects of ebselen were largely mimicked by lithium. These findings show that ebselen has similar neuropharmacological effects to lithium across a range of mouse models relevant to depression. The antidepressant potential of ebselen is discussed.</p>
spellingShingle Antoniadou, I
Investigation of the neurochemical, molecular and behavioural properties of the putative lithium-mimetic, ebselen
title Investigation of the neurochemical, molecular and behavioural properties of the putative lithium-mimetic, ebselen
title_full Investigation of the neurochemical, molecular and behavioural properties of the putative lithium-mimetic, ebselen
title_fullStr Investigation of the neurochemical, molecular and behavioural properties of the putative lithium-mimetic, ebselen
title_full_unstemmed Investigation of the neurochemical, molecular and behavioural properties of the putative lithium-mimetic, ebselen
title_short Investigation of the neurochemical, molecular and behavioural properties of the putative lithium-mimetic, ebselen
title_sort investigation of the neurochemical molecular and behavioural properties of the putative lithium mimetic ebselen
work_keys_str_mv AT antoniadoui investigationoftheneurochemicalmolecularandbehaviouralpropertiesoftheputativelithiummimeticebselen